D-0161-2023 Class III Terminated

Recalled by Lannett Company Inc. — Seymour, IN

FDA drug recall D-0161-2023 was initiated by Lannett Company Inc. on Nov 9, 2022 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specifications The recall status is terminated (terminated Jun 8, 2023). Affected quantity: 20,040 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 25, 2023
Initiation Date
Nov 9, 2022
Termination Date
Jun 8, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
20,040 bottles

Product description

Triamterene and Hydrochlorothiazide Capsules, USP (37.5 mg/25 mg), Rx Only, [100 or 1000 ] Capsules per bottle, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136. NDC 100 Count bottle: 0527-1632-01; NDC 1,000 bottle: 0527-1632-10

Reason for recall

Failed Impurity/Degradation Specifications

Distribution pattern

Nationwide USA

Code information

Lots: 21000279A (exp 01/2023), 20256320A (12/2022)

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0161-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0161-2023. Report a data issue: hello@regdatalab.com.